Bioequivalence To Duopa Could Mean Quick Path To Market For NeuroDerm In Parkinson’s

19 Jun 2015

With several companies working on new Parkinson’s therapies to maintain therapeutic levels of levodopa, NeuroDerm thinks it has a formulation that will offer similar benefits to AbbVie’s Duopa, with less invasive therapy.

NeuroDerm Ltd. thinks has a chance to get to market quickly in Europe, and possibly also in the U.S., with one of its subcutaneous liquid formulations of levodopa/carbidopa by demonstrating bioequivalence to AbbVie Inc.’s Duopa.

Following approval last October by the European Medicines Agency, NeuroDerm has launched a 24-patient, open-label pharmacokinetic study to determine dosing...